2012). The study revealed that phosphorylated β‐catenin‐positive osteocytes increased in patients with CKD compared with participants without CKD. More recently, animal experiments have shown that inhibition of Wnt antagonists, which act upstream of GSK‐3β, increases bone volume in CKD models (Fang et al. 2014; Moe et al. 2015). These results suggest that activation of the Wnt/β‐catenin signaling pathway has the potential to increase bone volume in CKD. However, it remains unclear whether direct inhibition of GSK‐3β increases bone volume in CKD. The gene discussed is GSK3B; the disease is chronic kidney disease.